Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(abiraterone)
2,223 results
  • Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. [Review]
    Urol Oncol. 2020 Jun 23 [Online ahead of print]Kafka M, Eder IE, … Heidegger I
  • Prostate cancer is one of the most common causes of death in males. Even if treatment is often of curative intent in early stages of the disease, up to 50% of patients relapse after primary therapy. Moreover, 10% to 15% of patients present in a primary metastatic stage of disease. In the past years the treatment landscape of metastatic castration-resistant prostate cancer expanded due to the deve…
  • Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. [Journal Article]
    J Clin Med. 2020 Jun 22; 9(6)Conteduca V, Caffo O, … De Giorgi U
  • Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investigate the association between ADT and immune disorders, considering a potential role of androgens in…
  • Slow tight binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. [Journal Article]
    J Pharmacol Exp Ther. 2020 Jun 17 [Online ahead of print]Cheong EJY, Nair PC, … Chan ECY
  • Substantial evidence underscores the clinical efficacy of inhibiting cytochrome P450 17A1 (CYP17A1)-mediated androgen biosynthesis by abiraterone for treatment of prostate oncology. Previous structural analysis and in vitro assays revealed inconsistencies surrounding the nature and potency of CYP17A1 inhibition by abiraterone. Here, we establish that abiraterone is a slow, tight binding inhibitor…
  • Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. [Journal Article]
    Expert Rev Anticancer Ther. 2020 Jun 25 [Online ahead of print]Manceau C, Mourey L, … Ploussard G
  • Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until invariable tumor regression. At the castration-resistant stage, metastatic disease becomes let…
  • Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer. [Journal Article]
    Int J Radiat Oncol Biol Phys. 2020 Jun 13 [Online ahead of print]Parikh NR, Chang EM, … Kishan AU
  • CONCLUSIONS: At 10 years, upfront MDT followed by salvage AAP+ADT is comparably cost-effective compared to upfront standard-of-care systemic therapy and may be considered a viable treatment strategy - especially in patients wishing to defer systemic therapy for quality-of-life or comorbidity concerns. Additional studies are needed to determine whether MDT causes a sustained meaningful delay in disease natural history, and whether any benefit exists in combining MDT with upfront advanced systemic therapy.
  • Advanced Prostate Cancer: Treatment Advances and Future Directions. [Review]
    Trends Cancer. 2020 Jun 10 [Online ahead of print]Swami U, R McFarland T, … Agarwal N
  • Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Appropriate drug selection rem…
  • Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. [Journal Article]
    Eur Urol. 2020 Jun 09 [Online ahead of print]Armstrong AJ, Lin P, … Beer TM
  • CONCLUSIONS: At the 5-yr data cutoff, 1382 of 1717 (80%) men had died. Enzalutamide reduced the hazard of death by 17% (hazard ratio 0.83; 95% confidence interval [CI] 0.75-0.93; p < 0.001), despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and enzalutamide, respectively. Median overall survival was 36 mo (95% CI 34-38) in the enzalutamide arm versus 31 mo (95% CI 29-34) in the placebo arm, with a median follow-up of 69 mo. Prognostic modeling showed 5-yr survival rates of 42%, 24%, and 5% for low-, intermediate-, and high-risk groups, respectively. Greater degrees of confirmed prostate-specific antigen declines (≤3 mo) were associated with greater 5-yr survival. A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6.9% vs 3.8%), with an increase in fatal cardiovascular events (1.6% vs 0.4%).With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events. PREVAIL is registered on ClinicalTrials.gov as NCT01212991.
  • Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT. [Journal Article]
    Clin Nucl Med. 2020 Jun 08 [Online ahead of print]Zukotynski KA, Jadvar H, … Winquist E
  • A 51-year-old man diagnosed with high-grade, high-volume metastatic castration-sensitive prostate adenocarcinoma received pelvic radiation, androgen deprivation therapy, and intravenous docetaxel. Serum prostate-specific antigen became undetectable following treatment. Within a year, his cancer progressed to castration-resistant disease, and he was treated with oral abiraterone acetate 1000 mg an…
  • Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. [Review]
    Heart Fail Rev. 2020 Jun 04 [Online ahead of print]Cereda V, Falbo PT, … Lanzetta G
  • Therapeutic intervention for prostate cancer mostly relies on eliminating circulating androgen or antagonizing its effect at the cellular level. As the use of endocrine therapies grows, an under-reported incidence of cardiovascular toxicities occurs in prostate cancer patients. In this review, we summarize data of clinical studies, investigating the cardiovascular and metabolic alterations associ…
  • Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. [Review]
    Crit Rev Oncol Hematol. 2020 May 24; 152:102994.Leone G, Buttigliero C, … Tucci M
  • Testosterone suppression by androgen deprivation therapy is the cornerstone of prostate cancer treatment. New-generation hormone therapies improved overall survival in castration-resistant prostate cancer. More recent trials showed a further increase in overall survival when enzalutamide or abiraterone are associated with androgen deprivation therapy in hormone-sensitive disease. However, a highe…
New Search Next